Payment overview · 2025
General Payments
$1,777.22
102 reported records · 28 companies
Healthcare provider profile · identity verified
Holly Mitchell, MD
Allopathic & Osteopathic Physicians|Internal Medicine · AMARILLO, TX · NPI 1881630622
Verified facts
What the public records show
CMS Open Payments records show Holly Mitchell, MD received $1,777.22 in general payments during 2025 across 102 reported records.
EMD Serono, Inc. accounted for 13.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 254 claims for Jardiance by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 254 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $245.91 | 13.8% | 17 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $223.41 | 12.6% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $220.47 | 12.4% | 16 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $164.37 | 9.2% | 12 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $157.99 | 8.9% | 7 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $114.11 | 6.4% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $109.74 | 6.2% | 5 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $59.18 | 3.3% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $38.23 | 2.1% | 2 | 2025 |
| QOL Medical, LLC | Unresolved — no canonical attribution shown | $36.27 | 2.0% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.38 | 1.9% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $33.26 | 1.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.84 | 1.9% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $32.57 | 1.8% | 2 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $28.00 | 1.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.62 | 1.5% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $24.96 | 1.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.51 | 1.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.35 | 1.1% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$19.06 | 1.1% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $18.88 | 1.1% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $18.43 | 1.0% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $18.20 | 1.0% | 1 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.83 | 1.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.98 | 1.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.07 | 0.9% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $15.12 | 0.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.48 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,777.22 | 102 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $220.47 | 16 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $213.38 | 15 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $164.37 | 12 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $161.36 | 6 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $100.17 | 5 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $96.04 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $82.77 | 4 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $81.01 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $59.18 | 3 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $47.32 | 2 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $42.23 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $38.23 | 2 | 2025 |
Source payment records
|
|||||
| Sucraid Normalized: sucraid |
Drug | QOL Medical, LLC | $36.27 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $33.38 | 1 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $33.26 | 1 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $33.26 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.84 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.84 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $32.57 | 2 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $28.00 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $26.62 | 4 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $25.37 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $24.96 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| SPINRAZA Normalized: spinraza |
Biological | Biogen, Inc. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.48 | 1 | 2025 |
Source payment records
|
|||||
| STELARA Normalized: stelara |
Biological | Janssen Biotech, Inc. | $12.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 254 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 72 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
254 | 51 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
254 | 51 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
72 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
107 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
166 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1540 | 368 |
| Atorvastatin Calcium | Atorvastatin Calcium | 785 | 186 |
| Gabapentin | Gabapentin | 660 | 145 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 511 | 123 |
| Pantoprazole Sodium | Pantoprazole Sodium | 484 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 454 | 110 |
| Losartan Potassium | Losartan Potassium | 418 | 111 |
| Furosemide | Furosemide | 395 | 98 |
| Metformin Hcl | Metformin Hcl | 364 | 86 |
| Simvastatin | Simvastatin | 358 | 92 |
| Potassium Chloride | Potassium Chloride | 352 | 91 |
| Omeprazole | Omeprazole | 331 | 79 |
| Lisinopril | Lisinopril | 283 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 271 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 262 | 68 |
| Ozempic | Semaglutide | 255 | 44 |
| Jardiance | Empagliflozin | 254 | 51 |
| Sertraline Hcl | Sertraline Hcl | 231 | 50 |
| Trazodone Hcl | Trazodone Hcl | 231 | 56 |
| Meloxicam | Meloxicam | 225 | 54 |
| Tramadol Hcl | Tramadol Hcl | 223 | 55 |
| Allopurinol | Allopurinol | 221 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 216 | 44 |
| Carvedilol | Carvedilol | 206 | 50 |
| Glimepiride | Glimepiride | 202 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 200 | 42 |
| Montelukast Sodium | Montelukast Sodium | 191 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 190 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 188 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 185 | 33 |
| Alendronate Sodium | Alendronate Sodium | 182 | 45 |
| Citalopram Hbr | Citalopram Hydrobromide | 173 | 42 |
| Synthroid | Levothyroxine Sodium | 168 | 41 |
| Eliquis | Apixaban | 166 | 28 |
| Spironolactone | Spironolactone | 153 | 42 |
| Alprazolam | Alprazolam | 149 | 29 |
| Bupropion Xl | Bupropion Hcl | 141 | 29 |
| Methocarbamol | Methocarbamol | 134 | 46 |
| Estradiol | Estradiol | 129 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 127 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 46 |
| Januvia | Sitagliptin Phosphate | 125 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 125 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 114 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 109 | 94 |
| Trulicity | Dulaglutide | 107 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 106 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 24 |
| Ezetimibe | Ezetimibe | 98 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 98 | 26 |
| Donepezil Hcl | Donepezil Hcl | 94 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 94 | 27 |
| Rybelsus | Semaglutide | 92 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 91 | 28 |
| Amitriptyline Hcl | Amitriptyline Hcl | 88 | 18 |
| Clonazepam | Clonazepam | 81 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 30 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 78 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 77 | 11 |
| Prednisone | Prednisone | 77 | 48 |
| Pioglitazone Hcl | Pioglitazone Hcl | 73 | 15 |
| Mounjaro | Tirzepatide | 72 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 71 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 69 | 16 |
| Warfarin Sodium | Warfarin Sodium | 69 | 13 |
| Lorazepam | Lorazepam | 68 | 12 |
| Famotidine | Famotidine | 63 | 18 |
| Pregabalin | Pregabalin | 63 | 17 |
| Metformin Hcl Er | Metformin Hcl | 62 | 19 |
| Lovastatin | Lovastatin | 61 | 16 |
| Mirtazapine | Mirtazapine | 60 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 59 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 59 | 31 |
| Atenolol | Atenolol | 58 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 57 | 12 |
| Memantine Hcl | Memantine Hcl | 57 | 13 |
| Valacyclovir | Valacyclovir Hcl | 57 | 32 |
| Verapamil Er | Verapamil Hcl | 56 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 42 |
| Cefuroxime | Cefuroxime Axetil | 48 | 39 |
| Celecoxib | Celecoxib | 48 | 13 |
| Ondansetron Odt | Ondansetron | 48 | 32 |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | suppressed |
| Fluconazole | Fluconazole | 47 | 33 |
| Cephalexin | Cephalexin | 46 | 40 |
| Myrbetriq | Mirabegron | 45 | 12 |
| Topiramate | Topiramate | 45 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 44 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 44 | 13 |
| Valsartan | Valsartan | 42 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 42 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 14 |
| Irbesartan | Irbesartan | 39 | suppressed |
| Lansoprazole | Lansoprazole | 39 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 39 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 38 | suppressed |
| Ramipril | Ramipril | 35 | suppressed |
| Glipizide Er | Glipizide | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | suppressed |
| Nystatin | Nystatin | 33 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 29 |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 29 |
| Ibandronate Sodium | Ibandronate Sodium | 29 | suppressed |
| Cefdinir | Cefdinir | 28 | 21 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 28 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 28 | suppressed |
| Verapamil Sr | Verapamil Hcl | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | 11 |
| Armour Thyroid | Thyroid,pork | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 24 |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Premarin | Estrogens, Conjugated | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | 13 |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 17 |
| Risedronate Sodium | Risedronate Sodium | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Scopolamine | Scopolamine | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Cartia Xt | Diltiazem Hcl | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 14 |
| Febuxostat | Febuxostat | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Klor-Con 10 | Potassium Chloride | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 14 | 14 |
| Ropinirole Er | Ropinirole Hcl | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 12 |
| Buprenorphine | Buprenorphine | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,777.22 · 102 records | EMD Serono, Inc. | AUSTEDO XR, BRIUMVI, Bafiertam, Briviact, DUPIXENT, Fintepla, Hizentra, IBSRELA, INBRIJA, INGREZZA, JARDIANCE, LEQEMBI, LEQVIO, MOUNJARO, NURTEC ODT, REXULTI, Rystiggo, SPINRAZA, STELARA, Sucraid, Sunosi, TREMFYA, TYSABRI, Tascenso ODT, ULTOMIRIS, UPLIZNA, VOQUEZNA, VUMERITY, VYEPTI, VYVGART HYTRULO, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error